These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary. Sakata K; Shigemasa K; Nagai N; Ohama K Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877 [TBL] [Abstract][Full Text] [Related]
9. Targeting the tumor microenvironment with chemically modified tetracyclines: inhibition of laminin 5 gamma2 chain promigratory fragments and vasculogenic mimicry. Seftor RE; Seftor EA; Kirschmann DA; Hendrix MJ Mol Cancer Ther; 2002 Nov; 1(13):1173-9. PubMed ID: 12479698 [TBL] [Abstract][Full Text] [Related]
10. [Primary study of vasculogenic mimicry induced by hypoxia in epithelial ovarian carcinoma]. Yao LQ; Feng YJ; Ding JX; Xu CJ; Jin HY; Yin LH Zhonghua Fu Chan Ke Za Zhi; 2005 Oct; 40(10):662-5. PubMed ID: 16277894 [TBL] [Abstract][Full Text] [Related]
11. Tumor blood vessels formation in osteosarcoma: vasculogenesis mimicry. Cai XS; Jia YW; Mei J; Tang RY Chin Med J (Engl); 2004 Jan; 117(1):94-8. PubMed ID: 14733782 [TBL] [Abstract][Full Text] [Related]
12. Molecular regulation of tumor cell vasculogenic mimicry by tyrosine phosphorylation: role of epithelial cell kinase (Eck/EphA2). Hess AR; Seftor EA; Gardner LM; Carles-Kinch K; Schneider GB; Seftor RE; Kinch MS; Hendrix MJ Cancer Res; 2001 Apr; 61(8):3250-5. PubMed ID: 11309274 [TBL] [Abstract][Full Text] [Related]
13. The involvement of apoptosis in melanoma vasculogenic mimicry. Vartanian AA; Burova OS; Stepanova EV; Baryshnikov AY Melanoma Res; 2007 Feb; 17(1):1-8. PubMed ID: 17235236 [TBL] [Abstract][Full Text] [Related]
14. Vasculogenic mimicry is associated with poor survival in patients with mesothelial sarcomas and alveolar rhabdomyosarcomas. Sun B; Zhang S; Zhao X; Zhang W; Hao X Int J Oncol; 2004 Dec; 25(6):1609-14. PubMed ID: 15547697 [TBL] [Abstract][Full Text] [Related]
15. The clinical significance of tumor cell-lined vasculature in ovarian carcinoma: implications for anti-vasculogenic therapy. Sood AK; Fletcher MS; Zahn CM; Gruman LM; Coffin JE; Seftor EA; Hendrix MJ Cancer Biol Ther; 2002; 1(6):661-4. PubMed ID: 12642690 [TBL] [Abstract][Full Text] [Related]
16. Shedding of membrane vesicles by tumor and endothelial cells. Dolo V; D'Ascenzo S; Giusti I; Millimaggi D; Taraboletti G; Pavan A Ital J Anat Embryol; 2005; 110(2 Suppl 1):127-33. PubMed ID: 16101030 [TBL] [Abstract][Full Text] [Related]
17. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Lin YG; Han LY; Kamat AA; Merritt WM; Landen CN; Deavers MT; Fletcher MS; Urbauer DL; Kinch MS; Sood AK Cancer; 2007 Jan; 109(2):332-40. PubMed ID: 17154180 [TBL] [Abstract][Full Text] [Related]
18. Angiogenesis, vasculogenesis, and vasculogenic mimicry in ovarian cancer. Tang HS; Feng YJ; Yao LQ Int J Gynecol Cancer; 2009 May; 19(4):605-10. PubMed ID: 19509557 [TBL] [Abstract][Full Text] [Related]
19. Membrane-type matrix metalloproteinase expression and matrix metalloproteinase-2 activation in primary human ovarian epithelial carcinoma cells. Fishman DA; Bafetti LM; Stack MS Invasion Metastasis; 1996; 16(3):150-9. PubMed ID: 9186550 [TBL] [Abstract][Full Text] [Related]
20. Molecular biology of breast cancer metastasis. Molecular expression of vascular markers by aggressive breast cancer cells. Hendrix MJ; Seftor EA; Kirschmann DA; Seftor RE Breast Cancer Res; 2000; 2(6):417-22. PubMed ID: 11250735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]